Antiviral Drug - Explore the Science & Experts | ideXlab



Scan Science and Technology

Contact Leading Edge Experts & Companies

Antiviral Drug

The Experts below are selected from a list of 39438 Experts worldwide ranked by ideXlab platform

Antiviral Drug – Free Register to Access Experts & Abstracts

Sina Bavari – One of the best experts on this subject based on the ideXlab platform.

  • Broad-spectrum coronavirus Antiviral Drug discovery
    Expert Opinion on Drug Discovery, 2019
    Co-Authors: Allison L. Totura, Sina Bavari

    Abstract:

    ABSTRACTIntroduction: The highly pathogenic coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are lethal zoonotic vi…

    Free Register to Access Article

  • broad spectrum coronavirus Antiviral Drug discovery
    Expert Opinion on Drug Discovery, 2019
    Co-Authors: Allison L. Totura, Sina Bavari

    Abstract:

    Introduction: The highly pathogenic coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are lethal zoonotic viruses th…

    Free Register to Access Article

Erik De Clercq – One of the best experts on this subject based on the ideXlab platform.

  • the next ten stories on Antiviral Drug discovery part e advents advances and adventures
    Medicinal Research Reviews, 2011
    Co-Authors: Erik De Clercq

    Abstract:

    This review article presents the fifth part (part E) in the series of stories on Antiviral Drug discovery. The ten stories belonging to this fifth part are dealing with (i) aurintricarboxylic acid; (ii) alkenyldiarylmethanes; (iii) human immunodeficiency virus (HIV) integrase inhibitors; (iv) lens epithelium-derived growth factor as a potential target for HIV proviral DNA integration; (v) the status presens of neuraminidase inhibitors NAIs in the control of influenza virus infections; (vi) the status presens on respiratory syncytial virus inhibitors; (vii) tricyclic (1,N-2-ethenoguanine)-based acyclovir and ganciclovir derivatives; (viii) glycopeptide antibiotics as Antivirals targeted at viral entry; (ix) the potential (off-label) use of cidofovir in the treatment of polyoma (JC and BK) virus infections; and (x) finally, thymidine phosphorylase as a target for both Antiviral and anticancer agents. © 2009 Wiley Periodicals, Inc. Med Res Rev, 31, No. 1, 118–160, 2010

    Free Register to Access Article

  • Antiviral Drug discovery ten more compounds and ten more stories part b
    Medicinal Research Reviews, 2009
    Co-Authors: Erik De Clercq

    Abstract:

    This review article that complements the previous review article on “The discovery of Antiviral agents: ten different compounds, ten different stories” presents ten more compounds and ten more stories in which I have been closely involved at one or another point of my scientific career: (i) interferon (IFN) (in particular, IFN-beta); (ii) poly(I).poly(C); (iii) suramin; (iv) novel acyclic nucleoside phosphonates; (v) the double proDrug of [9-(2-phosphonomethoxyethyl)guanine]; (vi) cyclic nucleoside phosphonates; (vii) picornavirus inhibitors; (viii) human immunodeficiency virus (HIV) co-receptor inhibitors; (ix) nonimmunosuppressive cyclosporin A analogues; and (x) bicyclic (furanopyrimidine) nucleoside analogues. With the exception of the HIV co-receptor CCR5 inhibitor none of the compounds described here have already been marketed (for the indication they were initially developed). Successful Antiviral Drug development depends on the interplay of three disciplines, chemistry, biology/medicine, and industry, crucial factors being open mindedness for the unexpected, preparedness to explore serendipitous observations, and perseverance (in trying) to overcome the hurdles or setbacks inevitably compounding any Drug development.

    Free Register to Access Article

  • A guided tour through the Antiviral Drug field
    Future Virology, 2006
    Co-Authors: Erik De Clercq

    Abstract:

    Approximately 40 compounds have been formally licensed for clinical use as Antiviral Drugs, with half of these in use for the treatment of HIV infections. The remaining have been approved for use in the therapy of herpes virus (herpes simplex virus, varicella zoster virus and cytomegalovirus), hepadnavirus, hepacivirus and myxovirus (influenza and respiratory syncytial virus) infections. New compounds are in clinical development or under preclinical evaluation, and again, half of these are intended to target HIV infections. However, quite a number of important viral pathogens (i.e., human papillomavirus, hepatitis C virus and hemorrhagic fever viruses) remain in need of effective and/or improved Antiviral therapies.

    Free Register to Access Article

Allison L. Totura – One of the best experts on this subject based on the ideXlab platform.

  • Broad-spectrum coronavirus Antiviral Drug discovery
    Expert Opinion on Drug Discovery, 2019
    Co-Authors: Allison L. Totura, Sina Bavari

    Abstract:

    ABSTRACTIntroduction: The highly pathogenic coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are lethal zoonotic vi…

    Free Register to Access Article

  • broad spectrum coronavirus Antiviral Drug discovery
    Expert Opinion on Drug Discovery, 2019
    Co-Authors: Allison L. Totura, Sina Bavari

    Abstract:

    Introduction: The highly pathogenic coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are lethal zoonotic viruses th…

    Free Register to Access Article